---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-002306"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T03:48:53.866409+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MannKind reports 2022 total revenues of $100M, up 32% YoY; Tyvaso DPI royalties $16M

## Summary
- Q4 2022 total revenues $36.1M (+188% YoY); full-year $99.8M (+32% vs 2021).
- Afrezza net revenue $43.3M in 2022 (+11%); V-Go contributed $12.9M after Q2 acquisition.
- Tyvaso DPI royalties $15.6M in 2022 ($9.1M in Q4); $37.9M manufacturing revenue deferred.
- Cash and investments $172.8M at Dec 31, 2022; INHALE-1 pediatric trial 50% enrolled.
- Inhaled clofazimine (MNKD-101) to enter adaptive Phase 2/3 study in H2 2023.

## SEC filing metadata
- accession: 0001564590-23-002306
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000156459023002306/0001564590-23-002306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000156459023002306/mnkd-8k_20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-002306
- JSON: https://secwatch.observer/filing/0001564590-23-002306.json
- Plain text: https://secwatch.observer/filing/0001564590-23-002306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.